SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (412)5/13/2000 8:44:00 AM
From: Biotech Jim  Respond to of 1169
 
Simply put, this is a great deal for VRTX. I guess the market was anticipating this deal and that is the reason for the current churning. It may be that this will last for a couple more weeks and then the stock will run. I like the computational approaches of VRTX in the context of both structure based design and homology modeling approaches for related kinase sequences in which structure is not yet available. I guess a big question is what biology will be brought to bear on potential therapeutic validation of the recently identified kinase targets. I know, I'm getting a bit ahead of myself here. Nonetheless, does anyone know what the Harvard proteomics collaboration specifically brings to the table?

Jim



To: tommysdad who wrote (412)5/16/2000 2:47:00 PM
From: biowa  Read Replies (1) | Respond to of 1169
 
td,

Not impugning the Novartis deal, VRTX is great science.

Ciba bought 49% of CHIR at a very healthy premium because they wanted to "access biotech," and felt that CHIR could do a better job than them at it. Put it in the "Where are they now file?"

biowa


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News